Holen Sie sich die Stockscreener-App
19.88
13.41%
2.35
Vorhandelsmarkt:
20.38
0.50
+2.52%
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
BEAM Therapeutics’ SWOT analysis: base editing pioneer’s stock faces pivotal year - Investing.com
H.C. Wainwright reiterates buy rating on Beam Therapeutics stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates buy rating on Beam Therapeutics stock - Investing.com
Cathie Wood’s ARK ETFs adjust holdings, buying GitLab and Beam Therapeutics stock - Investing.com Nigeria
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clini - GuruFocus
Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire
Beam Therapeutics (BEAM) Reports Strong Results for Sickle Cell Therapy - GuruFocus
Beam reports positive results from sickle cell disease treatment - Seeking Alpha
Beam Therapeutics reports positive data from sickle cell therapy trial - Investing.com
Beam Therapeutics Reports Positive Update From Sickle Cell Disease Trial - MarketScreener
Beam Therapeutics reports positive data from sickle cell therapy trial By Investing.com - Investing.com Nigeria
Beam Therapeutics (BEAM) Releases Promising Data from BEACON Trial | BEAM Stock News - GuruFocus
New Clinical Data: BEAM's Sickle Cell Gene Therapy Achieves Remarkable 60%+ Success Metric in All Patients - Stock Titan
Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab - Benzinga
ARK Investment Acquires 349K Shares of Beam Therapeutics (BEAM) | BEAM Stock News - GuruFocus
Tesla’s Driverless Robotaxis Are Operating On Texas Streets - The Globe and Mail
Beam Therapeutics Confirms Key Decisions at Annual Meeting - TipRanks
Beam Therapeutics Announces Pricing of Underwritten Offering - Revista ADVFN
Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - mx.advfn.com
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy - Yahoo Finance
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - The Globe and Mail
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates - The Globe and Mail
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR - mx.advfn.com
Beam gets FDA orphan drug status for sickle cell disease treatment - Seeking Alpha
Beam Therapeutics Says Potential Sickle Cell Therapy Receives FDA Orphan Drug Designation - marketscreener.com
Beam Therapeutics (BEAM) Gains FDA Orphan Drug Status for Sickle - GuruFocus
Beam Therapeutics’ BEAM-101 receives FDA orphan drug status for SCD treatment - Investing.com Nigeria
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Gra - GuruFocus
Beam Therapeutics Announces Orphan Drug Designation For BEAM-101 - Nasdaq
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | BEAM Stock News - GuruFocus
Beam Therapeutics Announces U.S. FDA Orphan Drug - GlobeNewswire
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease - Yahoo Finance
Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io
Trading (BEAM) With Integrated Risk Controls - news.stocktradersdaily.com
Beam Therapeutics’ BEAM-302 gains FDA orphan drug status for AATD treatment By Investing.com - Investing.com South Africa
FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)’ AATD Gene Therapy - Insider Monkey
Beam Therapeutics’ BEAM-302 gains FDA orphan drug status for AATD treatment - Investing.com India
FDA Grants Orphan Drug Status to Beam Therapeutics' (BEAM) BEAM-302 | BEAM Stock News - GuruFocus
Beam receives Orphan Drug status for genetic disorder asset BEAM-302 - Seeking Alpha
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted To BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) - marketscreener.com
Beam Therapeutics Scores Dual FDA Wins as Orphan Drug Status Follows Promising AATD Trial Results - Stock Titan
Beam Therapeutics: A Cautious Hold On A Base Editing Pioneer (NASDAQ:BEAM) - Seeking Alpha
Shareholders May Find It Hard To Justify Increasing Beam Therapeutics Inc.'s (NASDAQ:BEAM) CEO Compensation For Now - simplywall.st
Beam Therapeutics (BEAM) Secures FDA Orphan Designation for New - GuruFocus
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):